KL PHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
KL PHARMA
Largest movements
- Receivables within one year +€30,250
new in 2025: €30,250
- Cash -€8,375
down €8,375 (-20.7%), from €40,437 to €32,062
mainly Debts after one year (-€39,088) and Receivables within one year (-€30,250)
- Reserves +€50,690
up €50,690 (+16.1%), from €315,186 to €365,876
- Debts after one year -€39,088
down €39,088 (-23.3%), from €167,773 to €128,685
- Depreciation -€3,149
down €3,149 (-38.8%), from €8,115 to €4,967
- Gross operating margin -€1,521
down €1,521 (-1.7%), from €91,628 to €90,107
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €647,599 | €664,528 | +€16,929 | +2.6% |
| Fixed assets | 21/28 | €606,403 | €601,436 | -€4,967 | -0.8% |
| Tangible fixed assets | 22/27 | €4,967 | - | -€4,967 | |
| Furniture and vehicles | 24 | €4,967 | - | -€4,967 | |
| Financial fixed assets | 28 | €601,436 | €601,436 | = | 0.0% |
| Current assets | 29/58 | €41,196 | €63,091 | +€21,895 | +53.1% |
| Amounts receivable within one year | 40/41 | - | €30,250 | +€30,250 | |
| Trade receivables | 40 | - | €30,250 | +€30,250 | |
| Cash at bank and in hand | 54/58 | €40,437 | €32,062 | -€8,375 | -20.7% |
| Deferred charges and accrued income | 490/1 | €759 | €779 | +€20 | +2.6% |
| Total equity and liabilities | 10/49 | €647,599 | €664,528 | +€16,929 | +2.6% |
| Equity | 10/15 | €333,936 | €384,626 | +€50,690 | +15.2% |
| Contributions | 10/11 | €18,750 | €18,750 | = | 0.0% |
| Outside capital | 11 | €18,750 | €18,750 | = | 0.0% |
| Other | 1109/19 | €18,750 | €18,750 | = | 0.0% |
| Reserves | 13 | €315,186 | €365,876 | +€50,690 | +16.1% |
| Distributable reserves | 133 | €315,186 | €365,876 | +€50,690 | +16.1% |
| Amounts payable | 17/49 | €313,663 | €279,902 | -€33,761 | -10.8% |
| Amounts payable after more than one year | 17 | €167,773 | €128,685 | -€39,088 | -23.3% |
| Financial debts | 170/4 | €167,773 | €128,685 | -€39,088 | -23.3% |
| Amounts payable within one year | 42/48 | €136,719 | €140,943 | +€4,225 | +3.1% |
| Current portion of amounts payable after more than one year | 42 | €42,222 | €39,088 | -€3,134 | -7.4% |
| Trade debts | 44 | €515 | €505 | -€10 | -1.9% |
| Suppliers | 440/4 | €515 | €505 | -€10 | -1.9% |
| Taxes, remuneration and social security | 45 | €5,300 | €11,920 | +€6,619 | +124.9% |
| Taxes | 450/3 | €5,300 | €11,920 | +€6,619 | +124.9% |
| Other amounts payable | 47/48 | €88,681 | €89,430 | +€749 | +0.8% |
| Accrued charges and deferred income | 492/3 | €9,171 | €10,274 | +€1,103 | +12.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €8,115 | €4,967 | -€3,149 | -38.8% |
| Other operating charges | 640/8 | €1,208 | €1,306 | +€98 | +8.1% |
| Gross operating margin | 9900 | €91,628 | €90,107 | -€1,521 | -1.7% |
| Operating profit (loss) | 9901 | €82,304 | €83,834 | +€1,530 | +1.9% |
| Financial charges | 65/66B | €14,688 | €13,912 | -€776 | -5.3% |
| Recurring financial charges | 65 | €14,688 | €13,912 | -€776 | -5.3% |
| Profit (loss) for the period before taxes | 9903 | €67,617 | €69,923 | +€2,306 | +3.4% |
| Income taxes | 67/77 | €18,593 | €19,233 | +€639 | +3.4% |
| Profit (loss) for the period | 9904 | €49,023 | €50,690 | +€1,666 | +3.4% |
| Profit (loss) for the period to be appropriated | 9905 | €49,023 | €50,690 | +€1,666 | +3.4% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 8 October 2026 via checked.be.